ICLUSIG (PONATINIB)

Iclusig (ponatinib) is a cancer medicine that interferes with the growth of some cancer cells.

Iclusig is usually given after other similar medications have been tried without success.

Iclusig (Ponatinib) Tablets suppliers in India. Allevaire India Network New Delhi, INDIA.

Alleviare Life sciences Pvt. Ltd. is a consulting pharmaceutical company specialized in providing medicines under Named Patient Program/Manage Access Program. Named Patient Program/ Manage Access Program is a program designed by the government of India and governments of many countries worldwide for patients who have exhausted the treatment options available in their respective countries and are in need of latest medicines that are available in countries of Europe and USA.

The order for Iclusig (Ponatinib) Tablets will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

Iclusig is a kinase inhibitor indicated for the treatment of adult patients with chronic phase, accelerated phase, or last phase chronic myeloid leukemia (CML) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy or Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) that is resistant or intolerant to prior tyrosine kinase inhibitor therapy (1). This indication is based upon response rate. There are no trials verifying an improvement in disease-related symptoms or increased survival with Iclusig

Medicine Name: Iclusig
Generic Name: ponatinib
Approval Date: 2012
Available as (Form & Strength): Capsules: 1 mg, 2 mg, 3 mg, and 4 mg
Company Name: ARIAD Pharmaceuticals, Inc.